Tumefactive demyelination presenting during bevacizumab treatment

Claire M Rice; David Rossiter; Janev Fehmi; James C Stevens; Shelley A Renowden; Nicki Cohen; Clare Bailey; Neil J Scolding

doi:10.1136/bcr-2015-212173

Tumefactive demyelination presenting during bevacizumab treatment

BMJ Case Rep. 2015 Dec 16:2015:bcr2015212173. doi: 10.1136/bcr-2015-212173.

Authors

Claire M Rice¹, David Rossiter², Janev Fehmi², James C Stevens², Shelley A Renowden³, Nicki Cohen⁴, Clare Bailey⁵, Neil J Scolding¹

Affiliations

¹ Department of Neurology, North Bristol, NHS Trust Bristol, UK School of Clinical Sciences, University of Bristol, Bristol, UK.
² Department of Neurology, North Bristol, NHS Trust Bristol, UK.
³ Department of Neuroradiology, North Bristol, NHS Trust Bristol, UK.
⁴ School of Clinical Sciences, University of Bristol, Bristol, UK Department of Neuropathology, North Bristol, NHS Trust Bristol, UK.
⁵ Bristol Eye Hospital, Lower Maudlin Street, Bristol, UK.

Abstract

We report the emergence of tumefactive demyelination during treatment with intravitreal bevacizumab (Avastin). This is of particular significance given that bevacizumab is currently being assessed as a potential treatment option for neuromyelitis optica, another demyelinating condition.

2015 BMJ Publishing Group Ltd.

Publication types

Case Reports

MeSH terms

Angiogenesis Inhibitors / administration & dosage
Angiogenesis Inhibitors / adverse effects*
Bevacizumab / administration & dosage
Bevacizumab / adverse effects*
Child
Choroidal Neovascularization / pathology
Demyelinating Diseases / cerebrospinal fluid
Demyelinating Diseases / chemically induced*
Demyelinating Diseases / pathology
Female
Follow-Up Studies
Humans
Intravitreal Injections
Treatment Outcome

Substances

Angiogenesis Inhibitors
Bevacizumab